Related Experiment Video
Updated: Jul 3, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Structural characterization of mutant alpha-galactosidases causing Fabry disease
Kanako Sugawara1, Kazuki Ohno2, Seiji Saito3
1Department of Analytical Biochemistry, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan.
Structural modeling of alpha-galactosidase (GLA) in Fabry disease reveals distinct mutation patterns. Classic mutations cause large structural changes, while variant mutations result in smaller, surface-localized alterations, aiding in predicting disease outcomes.
Area of Science:
- Biochemistry
- Genetics
- Structural Biology
Background:
- Fabry disease is a genetic disorder caused by mutations in the alpha-galactosidase (GLA) gene, leading to glycolipid accumulation.
- Understanding the structural impact of GLA mutations is crucial for predicting disease progression and therapeutic efficacy.
Purpose of the Study:
- To construct structural models of mutant alpha-galactosidase (GLA) enzymes.
- To analyze the structural consequences of 212 reported Fabry disease-associated amino acid substitutions.
- To correlate structural changes with disease phenotype and potential therapeutic strategies.
Main Methods:
- Computational modeling of wild-type and mutant GLA proteins.
- Calculation of structural indexes including affected atom counts, root-mean-square distance, and solvent-accessible surface area.
- Geographical and subquantitative analysis of structural changes.
Main Results:
- Classic Fabry mutations typically induce large structural alterations, often in the protein core or active site.
- Variant Fabry mutations result in smaller, surface-localized structural changes.
- Mutations amenable to substrate analogue therapies exhibit small or surface-localized structural changes, irrespective of phenotype.
Conclusions:
- Structural investigation provides insights into the molecular basis of Fabry disease.
- Predicting disease outcomes and therapeutic responses can be enhanced by analyzing structural changes in GLA.
- This approach aids in personalized medicine for Fabry disease patients.
More Related Videos
06:02Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
Published on: November 28, 2025
06:13Determination of Glucan Chain Length Distribution of Glycogen Using the Fluorophore-Assisted Carbohydrate Electrophoresis (FACE) Method
Published on: March 31, 2022
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Lysosomal Hydrolases